Comparing laparoscopic and open surgery for right colon cancer
Official title: Comparison of Laparoscopic Versus Open Right Colectomy for Right Colon Cancer, According to the Complete Mesocolic Excision (CME) Principles: a Prospective Randomized Controlled Trial
Run by Larissa University Hospital · NCT05713903 · Data updated 2026-11-12
This study is testing whether laparoscopic surgery or open surgery is better for patients with right colon cancer in terms of recovery and cancer outcomes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 114 (estimated) |
| Sponsor | Larissa University Hospital Academic / other |
| Locations | 1 site (Larissa) |
| Status | Recruiting |
| Started | February 6, 2023 |
| Main results expected | January 10, 2027 |
| Study ends | January 10, 2028 |
| Registry record updated | September 4, 2025 |
| Trial ID | NCT05713903 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 90 with histologically confirmed right colon cancer who are eligible for elective surgery.
✕Probably not a fit
Patients with locally advanced disease, distant metastases, or those requiring emergency surgery will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to compare the effectiveness of laparoscopic versus open right colectomy for patients with right colon cancer, utilizing the complete mesocolic excision (CME) technique. It is designed as a prospective randomized controlled trial, focusing on various endpoints including the quality of surgical specimens and oncological outcomes. Additionally, the study will evaluate the early and late postoperative recovery associated with each surgical method.
Why it matters
Potential benefit: If successful, this study could provide insights into which surgical approach offers better outcomes for patients with right colon cancer.
How similar studies have gone: Previous studies have shown promising results with laparoscopic techniques in colorectal surgeries, suggesting potential benefits, although this specific comparison may be novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed right colon cancer (cecum, ascending colon, hepatic flexure) * Surgical resection based on the CME principles * Patient 18 to 90 years old * American Society of Anesthesiologists score ≤III * Τ≤3 * Elective operation * Signed informed consent of the patient Exclusion Criteria: * Non elective operation (hemorrhage, perforation, obstruction) * Locally advanced disease (T4) * Distant metastases (Stage IV) * American Society of Anesthesiologists ≥IV * Previous laparotomy * BMI \>35 kg/m2 * Active sepsis or systemic infection * Untreated physical and mental disability * Pregnancy or breast-feeding * Lack of compliance with the protocol process * Non-granting of signed informed consent
Where it's running
-
Department of Surgery, University Hospital of Larissa
Larissa, Greece Recruiting
Study contacts
- Principal investigator: Konstantinos Perivoliotis, MD — University Hospital of Larissa
- Study coordinator: Konstantinos Perivoliotis, MD
- Email: kperi19@gmail.com
- Phone: 2413501000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
-
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.
-
Tafolecimab with chemoimmunotherapy as neoadjuvant treatment for locally advanced colon cancer
This study tests whether adding tafolecimab to a chemoimmunotherapy regimen helps shrink locally advanced colon cancer before surgery in adults who have pMMR/MSS tumors.
-
Neoadjuvant pembrolizumab and porustobart for resectable MSS colon cancer
This trial tests whether giving pembrolizumab with porustobart before surgery can shrink MSS colon cancer and improve outcomes, comparing one versus two doses of porustobart.
-
DEM301 in advanced colorectal cancer: a first-in-human test
This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.
-
SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors
This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.